Astrazeneca (AZN) Capital Leases (2012 - 2026)

Astrazeneca (AZN) has reported Capital Leases for 12 consecutive years, with -$94.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Capital Leases fell 16.05% year-over-year to -$94.0 million; the TTM figure through Mar 2026 stood at -$94.0 million (down 16.05% YoY), while the FY2025 annual figure was -$372.0 million, down 17.72% from the prior year.
• Capital Leases came in at -$94.0 million for Q1 2026 at Astrazeneca, up from -$372.0 million in the prior quarter.
• The five-year high for Capital Leases was -$67.0 million in Q1 2023, with the low at -$372.0 million in Q4 2025.
• Average Capital Leases over 5 years is -$167.8 million, with a median of -$134.0 million recorded in 2022.
• Across the five-year window, Capital Leases plunged 87.32% in 2022 and rose 9.46% in 2023, its largest moves.
• Year by year, Capital Leases stood at -$134.0 million in 2022, then rose by 3.73% to -$129.0 million in 2023, then slumped by 144.96% to -$316.0 million in 2024, then dropped by 17.72% to -$372.0 million in 2025, then soared by 74.73% to -$94.0 million in 2026.
• According to Business Quant data, Capital Leases over the past three periods registered -$94.0 million, -$372.0 million, and -$273.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.